Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OXALIPLATIN Cause Malignant neoplasm progression? 1,189 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,189 reports of Malignant neoplasm progression have been filed in association with OXALIPLATIN (Oxaliplatin). This represents 2.1% of all adverse event reports for OXALIPLATIN.

1,189
Reports of Malignant neoplasm progression with OXALIPLATIN
2.1%
of all OXALIPLATIN reports
302
Deaths
247
Hospitalizations

How Dangerous Is Malignant neoplasm progression From OXALIPLATIN?

Of the 1,189 reports, 302 (25.4%) resulted in death, 247 (20.8%) required hospitalization, and 44 (3.7%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OXALIPLATIN. However, 1,189 reports have been filed with the FAERS database.

What Other Side Effects Does OXALIPLATIN Cause?

Diarrhoea (4,963) Nausea (4,250) Neuropathy peripheral (3,662) Off label use (3,603) Neutropenia (3,391) Vomiting (3,383) Disease progression (3,370) Thrombocytopenia (2,886) Dyspnoea (2,779) Pyrexia (2,269)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which OXALIPLATIN Alternatives Have Lower Malignant neoplasm progression Risk?

OXALIPLATIN vs OXAPROZIN OXALIPLATIN vs OXAZEPAM OXALIPLATIN vs OXCARBAZEPINE OXALIPLATIN vs OXITRIPTAN OXALIPLATIN vs OXOMEMAZINE

Related Pages

OXALIPLATIN Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression OXALIPLATIN Demographics